Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,758 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

NCT04128787
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG881 Formulation 1, AG881 Formulation 2, Omeprazole
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Results available

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin

NCT00970593
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
OAP-189, placebo comparator
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chula Vista, California • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

NCT04548219
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Nov 2, 2026, 3:24 PM EST
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Different Forms of TAK-994 in Healthy Adults

NCT04745767
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-994
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Nov 2, 2026, 3:24 PM EST
Active, not recruiting Phase 2 Interventional

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

NCT05340309
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
Biological · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

NCT05639894
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candidate, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
25
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

NCT04907539
View directory record Official record
Conditions
Colorectal Cancer
Interventions
RXC004, Nivolumab, Denosumab
Drug · Biological
Lead sponsor
Redx Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 2 Interventional

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

NCT00535470
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
0.04% Mechlorethamine gel
Drug
Lead sponsor
Yaupon Therapeutics
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Stanford, California • Chicago, Illinois • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

NCT01668537
View directory record Official record
Conditions
Smallpox
Interventions
LF formulation of IMVAMUNE®, FD formulation of IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

NCT02641353
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Tablet, Apremilast Oral Suspension
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

NCT06128733
View directory record Official record
Conditions
Meningococcal Immunisation, Healthy Volunteers
Interventions
Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
46
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 2 Interventional Results available

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00730158
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
KD018, Irinotecan, Placebo
Drug
Lead sponsor
Edward Chu, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Nov 2, 2026, 3:24 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay

NCT02823509
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY 987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

NCT06761898
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-43395
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

TP-3654 Food Effect Study

NCT07492355
View directory record Official record
Conditions
Myelofibroses
Interventions
TP-3654
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443898
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Nov 2, 2026, 3:24 PM EST
Recruiting Phase 1Phase 2 Interventional

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
Procedure · Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 2, 2026, 3:24 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

NCT00838630
View directory record Official record
Conditions
Healthy
Interventions
Cilostazol 100 mg tablets, Pletal® 100 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Nov 2, 2026, 3:24 PM EST